Advertisement

Digestive Diseases and Sciences

, Volume 55, Issue 5, pp 1255–1263 | Cite as

Omeprazole Induces Gastric Permeability to Digoxin

  • M. Gabello
  • M. C. Valenzano
  • M. Barr
  • P. Zurbach
  • J. M. Mullin
Original Article

Abstract

Previous animal and patient-based studies have shown that omeprazole induces a transepithelial paracellular gastric leak. This study reports on the potential for an omeprazole-induced leak of drugs with narrow therapeutic windows. Ussing chamber experiments investigated the effects of omeprazole on rat gastric corpus permeability to the drugs, digoxin and phenytoin. Digoxin (780 MW) permeated the gastric mucosa at an accelerated rate in the presence of omeprazole. This leak could contribute to dangerous elevations of blood digoxin levels in certain situations. Omeprazole was found to have no effect on the flux rate of phenytoin (252 MW). The tight-junctional leak generated by omeprazole thus exhibits specificity to the types of molecules it allows to permeate through the gastric mucosa. This leak may pose a clinical danger by increasing drug uptake into the bloodstream, a phenomenon which would act synergistically with the effect of omeprazole on inhibiting liver cytochrome P450s that remove drugs from the bloodstream, thereby elevating drug blood levels.

Keywords

Omeprazole Proton pump inhibitor Tight junction Transepithelial Paracellular Digoxin 

Abbreviations

PPI

Proton pump inhibitor

TLC

Thin-layer chromatography

LSC

Liquid scintillation counting

Notes

Acknowledgments

We would like to thank the GI fellows, Keith R. Kearney, D.O. and Kevin R. Wolov, D.O., for their helpful input and for sharing their medical expertise. This work was supported by the Sharpe/Strumia Foundation.

References

  1. 1.
    Mullin JM, Valenzano MC, Whitby M et al. Esomeprazole induces upper gastrointestinal tract transmucosal permeability (R2). Aliment Pharmacol Ther. 2008.Google Scholar
  2. 2.
    Murray LJ, Gabello M, Rudolph DS et al. Transmucosal gastric leak induced by proton pump inhibitors. Dig Dis Sci. 2009.Google Scholar
  3. 3.
    Hopkins AM, McDonnell C, Breslin NP, O’Morain CA, Baird AW. Omeprazole increases permeability across isolated rat gastric mucosa pre-treated with an acid secretagogue. J Pharm Pharmacol. 2002;54:341–347. doi: 10.1211/0022357021778583.CrossRefPubMedGoogle Scholar
  4. 4.
    Mulrow CD, Feussner JR, Velez R. Reevaluation of digitalis efficacy. New light on an old leaf. Ann Intern Med. 1984;101:113–117.PubMedGoogle Scholar
  5. 5.
    Appleton R, Macleod S, Martland T. Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. Cochrane Database Syst Rev. 2008;3:CD001905.PubMedGoogle Scholar
  6. 6.
    Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301:937–944. doi: 10.1001/jama.2009.261.CrossRefPubMedGoogle Scholar
  7. 7.
    Peterson KU. Review article: Omeprazole and the cytochrome P450 system. Aliment Pharmacol Ther. 1995;9:1–9.Google Scholar
  8. 8.
    Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs. 2003;63:2739–2754. doi: 10.2165/00003495-200363240-00004.CrossRefPubMedGoogle Scholar
  9. 9.
    Dobson JG Jr, Kidder GW. Edge damage effect in vitro frog skin preparations. Am J Physiol. 1968;214:719–724.PubMedGoogle Scholar
  10. 10.
    Walser M. Role of edge damage in sodium permeability of toad bladder and a means of avoiding it. Am J Physiol. 1970;219:252–255.PubMedGoogle Scholar
  11. 11.
    Svelto M, Perrini MCR, Lippe C. Properties of the frog skin at various degrees of edge damage. Arch Int Physiol Biochim. 1975;83:837–843. doi: 10.3109/13813457509069514.CrossRefPubMedGoogle Scholar
  12. 12.
    Kleinzeller A, McAvoy EM, McKibbin RD. Active renal hexose transport. Structural requirements. Biochim Biophys Acta. 1980;600:513–529. doi: 10.1016/0005-2736(80)90453-8.CrossRefPubMedGoogle Scholar
  13. 13.
    Humphries TJ, Merritt GJ. Drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther. 1999;13(Suppl 3):18–26. doi: 10.1046/j.1365-2036.1999.00021.x. (Review article).CrossRefPubMedGoogle Scholar
  14. 14.
    Andersson T, Lagerström PO, Unge P. A study of the interaction between omeprazole and phenytoin in epileptic patients. Ther Drug Monit. 1990;12:329–333.PubMedCrossRefGoogle Scholar
  15. 15.
    Bachmann KA, Sullivan TJ, Jauregui L, Reese JH, Miller K, Levine L. Absence of an inhibitory effect of omeprazole and nizatidine on phenytoin disposition, a marker of CYP2C activity. Br J Clin Pharmacol. 1993;36:380–382.PubMedGoogle Scholar
  16. 16.
    Middle MV, Müller FO, Schall R, et al. No influence of pantoprazole on the pharmacokinetics of phenytoin. Clin Pharmacol Ther. 1996;34:S72–S75.Google Scholar
  17. 17.
    Karol MD, Locke CS, Cavanaugh JH. Lack of pharmacokinetic interaction between lansoprazole and intravenously administered phenytoin. J Clin Pharmacol. 1999;39:1283–1289. doi: 10.1177/00912709922011971.CrossRefPubMedGoogle Scholar
  18. 18.
    Howden CW. Clinical pharmacology of omeprazole. Clin Pharmacokinet. 1991;20:38–49. doi: 10.2165/00003088-199120010-00003.CrossRefPubMedGoogle Scholar
  19. 19.
    Andersson T. Omeprazole drug interaction studies. Clin Pharmacokinet. 1991;21:195–212. doi: 10.2165/00003088-199121030-00004.CrossRefPubMedGoogle Scholar
  20. 20.
    Cederberg C, Andersson T, Skånberg I. Omeprazole: pharmacokinetics and metabolism in man. Scand J Gastroenterol. 1989;166:33–42. doi: 10.3109/00365528909091241.CrossRefGoogle Scholar
  21. 21.
    Robertson DS. The chemical reactions in the human stomach and the relationship to metabolic disorders. Med Hypotheses. 2005;64:1127–1131. doi: 10.1016/j.mehy.2004.12.018.CrossRefPubMedGoogle Scholar
  22. 22.
    Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289:871–878. doi: 10.1001/jama.289.7.871.CrossRefPubMedGoogle Scholar
  23. 23.
    Steinijans VW, Huber R, Hartmann M, et al. Lack of pantoprazole drug interactions in man. Int J Clin Pharmacol Ther. 1994;32:385–399.PubMedGoogle Scholar
  24. 24.
    Oosterhuis B, Jonkman JH, Andersson T, Zuiderwijk PB, Jedema JN. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmacol. 1991;32:569–572.PubMedGoogle Scholar
  25. 25.
    Kiley CA, Cragin DJ, Roth BJ. Omeprazole-associated digoxin toxicity. South Med J. 2007;100:400–402.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • M. Gabello
    • 1
    • 2
  • M. C. Valenzano
    • 1
  • M. Barr
    • 3
  • P. Zurbach
    • 4
  • J. M. Mullin
    • 1
    • 5
  1. 1.Lankenau Institute for Medical ResearchWynnewoodUSA
  2. 2.Department of BiologySaint Joseph’s UniversityPhiladelphiaUSA
  3. 3.Department of MedicineLankenau HospitalWynnewoodUSA
  4. 4.Department of ChemistrySaint Joseph’s UniversityPhiladelphiaUSA
  5. 5.Division of GastroenterologyLankenau HospitalWynnewoodUSA

Personalised recommendations